{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:27:17Z","timestamp":1790908037204,"version":"4.1.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1016\/j.ejca.2010.03.021","type":"journal-article","created":{"date-parts":[[2010,5,6]],"date-time":"2010-05-06T08:50:49Z","timestamp":1273135849000},"page":"1724-1734","source":"Crossref","is-referenced-by-count":28,"title":["Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy"],"prefix":"10.1016","volume":"46","author":[{"given":"Roland","family":"Hubaux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Vandermeers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Crisanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veena","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ars\u00e8ne","family":"Burny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Mascaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Albelda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Willems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2010.03.021_bib1","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(05)67569-1","article-title":"Small-cell lung cancer","volume":"366","author":"Jackman","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2010.03.021_bib2","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(00)82038-3","article-title":"Lung cancer","volume":"355","author":"Hoffman","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2010.03.021_bib3","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1200\/JCO.2005.04.4859","article-title":"Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database","volume":"24","author":"Govindan","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.03.021_bib4","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.2165\/00003495-200767150-00003","article-title":"Modern management of small-cell lung cancer","volume":"67","author":"Ferraldeschi","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.ejca.2010.03.021_bib5","first-page":"CD006849","article-title":"Platinum versus non-platinum chemotherapy regimens for small cell lung cancer","author":"Amarasena","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejca.2010.03.021_bib6","doi-asserted-by":"crossref","first-page":"259S","DOI":"10.1378\/chest.123.1_suppl.259S","article-title":"Small cell lung cancer","volume":"123","author":"Simon","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.ejca.2010.03.021_bib7","unstructured":"Treatment of small cell lung cancer: extensive diseases. Guidelines of clinical practice made by the European Lung Cancer Working Party. Rev Med Brux 2008;29:455\u201370."},{"key":"10.1016\/j.ejca.2010.03.021_bib8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0169-5002(00)00127-6","article-title":"A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis","volume":"30","author":"Mascaux","year":"2000","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2010.03.021_bib9","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.1999.17.2.658","article-title":"Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer","volume":"17","author":"von Pawel","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.03.021_bib10","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nrc1799","article-title":"Epigenetic gene silencing in cancer \u2013 a mechanism for early oncogenic pathway addiction?","volume":"6","author":"Baylin","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2010.03.021_bib11","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1742-7843.2008.00325.x","article-title":"Epigenetic changes in cancer as potential targets for prophylaxis and maintenance therapy","volume":"103","author":"Gronbaek","year":"2008","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.ejca.2010.03.021_bib12","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1016\/j.ejca.2009.04.038","article-title":"Frequent hypermethylation of RASSF1A tumour suppressor gene promoter and presence of Merkel cell polyomavirus in small cell lung cancer","volume":"45","author":"Helmbold","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2010.03.021_bib13","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jss.2006.12.555","article-title":"The HDAC inhibitor trichostatin A inhibits growth of small cell lung cancer cells","volume":"142","author":"Platta","year":"2007","journal-title":"J Surg Res"},{"key":"10.1016\/j.ejca.2010.03.021_bib14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jss.2008.03.008","article-title":"Valproic acid induces Notch1 signaling in small cell lung cancer cells","volume":"148","author":"Platta","year":"2008","journal-title":"J Surg Res"},{"key":"10.1016\/j.ejca.2010.03.021_bib15","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/ijc.10921","article-title":"Antiproliferative effects of the histone deacetylase inhibitor FR901228 on small-cell lung cancer lines and drug-resistant sublines","volume":"104","author":"Tsurutani","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2010.03.021_bib16","doi-asserted-by":"crossref","first-page":"10309","DOI":"10.1073\/pnas.0504248102","article-title":"Valproate activates bovine leukemia virus gene expression, triggers apoptosis, and induces leukemia\/lymphoma regression in vivo","volume":"102","author":"Achachi","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ejca.2010.03.021_bib17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2141.2008.07426.x","article-title":"Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells","volume":"144","author":"Bouzar","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2010.03.021_bib18","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1158\/1535-7163.MCT-09-0138","article-title":"The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer","volume":"8","author":"Crisanti","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2010.03.021_bib19","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1158\/1078-0432.CCR-08-1579","article-title":"Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma","volume":"15","author":"Vandermeers","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2010.03.021_bib20","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1056\/NEJM199601183340308","article-title":"Antiepileptic drugs","volume":"334","author":"Brodie","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2010.03.021_bib21","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0301-0082(82)90010-7","article-title":"Mechanism of anticonvulsant action of valproate","volume":"19","author":"Chapman","year":"1982","journal-title":"Prog Neurobiol"},{"issue":"Suppl. 2","key":"10.1016\/j.ejca.2010.03.021_bib22","first-page":"25","article-title":"Pharmacokinetics, drug interactions, and tolerability of valproate","volume":"37","author":"DeVane","year":"2003","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.ejca.2010.03.021_bib23","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0140-6736(82)90018-6","article-title":"Valproic acid and spina bifida","volume":"2","author":"Bjerkedal","year":"1982","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2010.03.021_bib24","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/00001813-199609000-00008","article-title":"Antitumor activity of sodium valproate in cultures of human neuroblastoma cells","volume":"7","author":"Cinatl","year":"1996","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ejca.2010.03.021_bib25","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1158\/0008-5472.CAN-03-0799","article-title":"Histone deacetylase is a target of valproic acid-mediated cellular differentiation","volume":"64","author":"Gurvich","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2010.03.021_bib26","doi-asserted-by":"crossref","first-page":"36734","DOI":"10.1074\/jbc.M101287200","article-title":"Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen","volume":"276","author":"Phiel","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejca.2010.03.021_bib27","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1146\/annurev.biochem.70.1.81","article-title":"Histone acetyltransferases","volume":"70","author":"Roth","year":"2001","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.ejca.2010.03.021_bib28","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/nar\/27.3.711","article-title":"Chromatin disruption and modification","volume":"27","author":"Wolffe","year":"1999","journal-title":"Nucl Acids Res"},{"key":"10.1016\/j.ejca.2010.03.021_bib29","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0959-437X(03)00020-0","article-title":"Functional consequences of histone modifications","volume":"13","author":"Iizuka","year":"2003","journal-title":"Curr Opin Genet Dev"},{"key":"10.1016\/j.ejca.2010.03.021_bib30","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","article-title":"Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells","volume":"20","author":"Gottlicher","year":"2001","journal-title":"EMBO J"},{"key":"10.1016\/j.ejca.2010.03.021_bib31","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1158\/1535-7163.MCT-05-0480","article-title":"Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells","volume":"5","author":"Hrzenjak","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2010.03.021_bib32","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1158\/1535-7163.MCT-05-0184","article-title":"Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC","volume":"4","author":"Li","year":"2005","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2010.03.021_bib33","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1111\/j.1349-7006.2008.00793.x","article-title":"Valproic acid resensitizes cisplatin-resistant ovarian cancer cells","volume":"99","author":"Lin","year":"2008","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ejca.2010.03.021_bib34","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1593\/neo.05823","article-title":"Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L\/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation","volume":"8","author":"Ziauddin","year":"2006","journal-title":"Neoplasia"},{"key":"10.1016\/j.ejca.2010.03.021_bib35","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ctrv.2007.11.003","article-title":"Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors","volume":"34","author":"Duenas-Gonzalez","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2010.03.021_bib36","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1081\/CLT-100102388","article-title":"Multicenter case series of valproic acid ingestion: serum concentrations and toxicity","volume":"38","author":"Spiller","year":"2000","journal-title":"J Toxicol Clin Toxicol"},{"key":"10.1016\/j.ejca.2010.03.021_bib37","doi-asserted-by":"crossref","unstructured":"Stewart DJ. Tumor and host factors that may limit efficacy of chemotherapy in non-small and small cell lung cancer. Crit Rev Oncol\/Hematol 2009; in press. doi:10.1016\/j.critrevonc.2009.11.006.","DOI":"10.1016\/j.critrevonc.2009.11.006"},{"key":"10.1016\/j.ejca.2010.03.021_bib38","doi-asserted-by":"crossref","first-page":"163S","DOI":"10.1378\/chest.117.4_suppl_1.163S","article-title":"New therapeutic strategies for lung cancer: biology and molecular biology come of age","volume":"117","author":"Bunn","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.ejca.2010.03.021_bib39","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1158\/1535-7163.1397.3.11","article-title":"The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells","volume":"3","author":"Doi","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2010.03.021_bib40","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0092-8674(00)81590-1","article-title":"Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis","volume":"94","author":"Li","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2010.03.021_bib41","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0092-8674(00)81589-5","article-title":"Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors","volume":"94","author":"Luo","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2010.03.021_bib42","first-page":"2922","article-title":"The expanding role of mitochondria in apoptosis","volume":"15","author":"Wang","year":"2001","journal-title":"Genes Dev"},{"issue":"1","key":"10.1016\/j.ejca.2010.03.021_bib43","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1038\/onc.2009.47","article-title":"Bid: a Bax-like BH3 protein","volume":"27S","author":"Billen","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2010.03.021_bib44","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1158\/1535-7163.327.3.3","article-title":"Down-regulation of Bcl-2 is associated with cisplatin resistance in human small cell lung cancer H69 cells","volume":"3","author":"Kumar","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2010.03.021_bib45","doi-asserted-by":"crossref","first-page":"16034","DOI":"10.1074\/jbc.M513587200","article-title":"PUMA Dissociates Bax and Bcl-X(L) to induce apoptosis in colon cancer cells","volume":"281","author":"Ming","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejca.2010.03.021_bib46","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1073\/pnas.2627984100","article-title":"PUMA mediates the apoptotic response to p53 in colorectal cancer cells","volume":"100","author":"Yu","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ejca.2010.03.021_bib47","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1182\/blood-2003-01-0211","article-title":"Cleavage of Bax to p18 Bax accelerates stress-induced apoptosis, and a cathepsin-like protease may rapidly degrade p18 Bax","volume":"102","author":"Cao","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2010.03.021_bib48","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1046\/j.1471-4159.2001.00368.x","article-title":"Cleavage of Bax is mediated by caspase-dependent or -independent calpain activation in dopaminergic neuronal cells: protective role of Bcl-2","volume":"77","author":"Choi","year":"2001","journal-title":"J Neurochem"},{"key":"10.1016\/j.ejca.2010.03.021_bib49","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/1097-4644(20010101)80:1<53::AID-JCB60>3.0.CO;2-E","article-title":"N-terminal cleavage of bax by calpain generates a potent proapoptotic 18-kDa fragment that promotes bcl-2-independent cytochrome C release and apoptotic cell death","volume":"80","author":"Gao","year":"2000","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.ejca.2010.03.021_bib50","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/sj.onc.1202034","article-title":"Bax cleavage is mediated by calpain during drug-induced apoptosis","volume":"17","author":"Wood","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2010.03.021_bib51","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1158\/1541-7786.MCR-07-0324","article-title":"Histone deacetylase inhibitors: overview and perspectives","volume":"5","author":"Dokmanovic","year":"2007","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.ejca.2010.03.021_bib52","doi-asserted-by":"crossref","first-page":"779","DOI":"10.4161\/cc.3.6.927","article-title":"Histone-deacetylase inhibitors for the treatment of cancer","volume":"3","author":"Lindemann","year":"2004","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ejca.2010.03.021_bib53","first-page":"7291","article-title":"Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA","volume":"63","author":"Kim","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2010.03.021_bib54","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/81671","article-title":"Histone deacetylase interacts directly with DNA topoisomerase II","volume":"26","author":"Tsai","year":"2000","journal-title":"Nat Genet"},{"key":"10.1016\/j.ejca.2010.03.021_bib55","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S1097-2765(04)00094-2","article-title":"Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis","volume":"13","author":"Cohen","year":"2004","journal-title":"Mol Cell"},{"key":"10.1016\/j.ejca.2010.03.021_bib56","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1677\/joe.1.06970","article-title":"Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells","volume":"191","author":"Catalano","year":"2006","journal-title":"J Endocrinol"},{"key":"10.1016\/j.ejca.2010.03.021_bib57","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1158\/0008-5472.CAN-04-2478","article-title":"Valproic acid alters chromatin structure by regulation of chromatin modulation proteins","volume":"65","author":"Marchion","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2010.03.021_bib58","first-page":"1486","article-title":"Management of small-cell lung cancer: incremental changes but hope for the future","volume":"22","author":"Hann","year":"2008","journal-title":"Oncology"},{"key":"10.1016\/j.ejca.2010.03.021_bib59","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.2008.20.1061","article-title":"Phase III trial of irinotecan\/cisplatin compared with etoposide\/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124","volume":"27","author":"Lara","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.03.021_bib60","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/1078-0432.CCR-08-1930","article-title":"Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I\/II trial of valproic acid and epirubicin\/FEC","volume":"15","author":"Munster","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2010.03.021_bib61","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1200\/JCO.2006.08.6165","article-title":"Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study","volume":"25","author":"Munster","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804910002522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804910002522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T02:03:05Z","timestamp":1685584985000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804910002522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":61,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S0959804910002522"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2010.03.021","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}